AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02589756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The nut group
Description: At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
Study NCT02589756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The nut group
Description: At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
Study NCT02955719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT02955719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Study NCT02955719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT/Psychological Therapy
Study NCT02955719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric Consultation
Study NCT02955719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Resources
Study NCT03478592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitrification technique
Description: Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
Study NCT02385591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Support
Description: telephone-based physical activity advice and support delivered by a trained professional facilitator.
Study NCT02385591 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS Support
Description: Telephone-based physical activity advice and support delivered by SMS.
Study NCT03215186 — intervention group
Intervention type: OTHER
Intervention: observational study
Study NCT03563911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness-Based Intervention (BMBI)
Description: The BMBI is be based on a BMBI which demonstrated analgesic effects in a previous study. Relative to full-length interventions, we will employ a brief intervention; the 20-minute BMBI session will include education on the foundational concepts of mindfulness and its relevance to chronic pain (5 minutes) and a guided mindfulness practice involving focused attention on the breath and monitoring of thoughts, feelings, and body sensations (15 minutes). BMBI participants will be encouraged to practice the taught mindfulness technique at home at least 20 minutes/day for 1 week (a handout and link to an online guided mindfulness practice will be provided).
Study NCT03563911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control/Nutrition Education
Description: The Control intervention will involve nutrition education, adapted from an existing manual of cognitive-behavioral therapy for opioid-treated chronic pain. Control intervention protocol will match the BMBI in terms of time / structure to control for the non-specific, non-mindfulness effects of BMBI. The 20-minute Control session will include education on the relationship between diet and pain (10 minutes) and recommendations for a healthy diet (10 minutes). Control participants will be encouraged to prepare healthy meals at home at least 20 minutes/day for 1 week (a handout and link to online resources will be provided).
Study NCT00403507 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Participation in a monitored exercise program
Description: No contact with control group during 20 weeks.
Study NCT00403507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized aerobic and strength training.
Description: Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
Study NCT02775591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9701
Description: DA-9701 30mg Tablet
Study NCT02775591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-9701
Description: DA-9701 30mg Tablet
Study NCT03337243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAM and HUMCWJ Injections
Description: SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.
Study NCT01796418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost sodium
Study NCT04117919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paper mulberry leaf
Description: Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
Study NCT04117919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone (Encort-A) 0.1%15g/Tube
Description: only Topical steroids
Study NCT04117919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (Encort-A) 0.1%15g/Tube
Description: only Topical steroids
Study NCT04037774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: comparision of different doses of dexmedetomidine used intrathecally
Study NCT04037774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: addition of placebo with local anesthetic to create a control group
Study NCT01053000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazorac
Description: compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
Study NCT02586246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870
Description: Self-injection
Study NCT01547130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal (0.9%) saline
Description: A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
Study NCT01547130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HalfLytely
Description: A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
Study NCT03557879 — intervention group
Intervention type: GENETIC
Intervention: Exome sequencing
Description: DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)
Study NCT02549027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Oral MK-1064 tablets (10 and 50 mg strengths)
Study NCT02549027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: Oral MK-6096 tablets (5 mg strength)
Study NCT02775591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-9701 placebo
Description: Placebo pill manufactured to mask DA-9701 30mg Tablet
Study NCT00422630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The DASH diet
Description: The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
Study NCT00422630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The low glycemic Index Diet
Description: The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
Study NCT00422630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced calorie American Diet
Description: The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
Study NCT05347680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubating Laryngeal Tube Suction
Description: Intubating Laryngeal Tube Suction
Study NCT05347680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraGain Laryngeal Mask
Description: Ambu AuraGain Laryngeal Mask
Study NCT03583268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
Study NCT03583268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
Study NCT02540187 — intervention group
Intervention type: OTHER
Intervention: blood specimen
Study NCT02749006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
Study NCT02749006 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
Study NCT00663806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cipro XR (Ciprofloxacin, BAYQ3939)
Description: Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
Study NCT00663806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cipro XR (Ciprofloxacin, BAYQ3939)
Description: Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
Study NCT03440151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contralateral submental flap for tongue cancer defect
Description: Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted.
Study NCT03440151 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary closure for tongue cancer defect
Description: Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
Study NCT04568486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes Empowerment Education Program
Description: The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
Study NCT03702569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Left ventricular global longitudinal strain measure
Description: Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
Study NCT01814397 — intervention group
Intervention type: DRUG
Intervention: Anastrozole
Description: 1 mg orally daily
Study NCT01814397 — intervention group
Intervention type: DRUG
Intervention: exemestane
Description: 25 mg orally daily
Study NCT01814397 — intervention group
Intervention type: DRUG
Intervention: letrozole
Description: 2.5 mg orally daily
Study NCT02963168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oradoxel
Description: oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
Study NCT01364454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eligible patients' paper-based reminder
Description: Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
Study NCT01139203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine adefovir entecavir HBIG
Description: lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
Study NCT00939289 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring
Description: Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
Study NCT04183504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief parenting intervention
Description: Coaching session on positive parenting practices and promoting child development
Study NCT05346744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chairside CAD/CAM ceramic materials for dental restoration
Description: 6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)
Study NCT00879151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adolescents
Description: The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
Study NCT00879151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy
Description: SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
Study NCT00879151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Therapy for Bulimia Nervosa
Description: FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
Study NCT02083341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lelo® Siri vibrator
Description: external vibration device
Study NCT02083341 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lelo® Siri vibrator with vibration component removed
Description: external vibration device - sham
Study NCT02589756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The control group
Description: After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
Study NCT01929915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural patient controlled analgesia
Description: Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
Study NCT01929915 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous patient controlled analgesia
Description: Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
Study NCT01584102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group fitness + education
Description: 15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
Study NCT01584102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group fitness classes only
Description: 15 weeks biweekly group fitness
Study NCT02837198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Study NCT00731341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation for the treatment of uterine fibroids
Description: Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
Study NCT03344094 — intervention group
Intervention type: DRUG
Intervention: ocrelizumab
Description: FDA-approved MS drugs
Study NCT01693822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.
Study NCT03548025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-703 (Treatment group)
Description: Treatment with BTL-FR2000 Device
Study NCT04182399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide Capsules
Description: anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
Study NCT02837198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiroxostat
Study NCT02465216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02465216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 + GLA-SE
Study NCT01441206 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rifampin
Description: Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth \< 32 weeks - PNA \< 14 days: 10 mg/kg QD GA at birth \< 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA \< 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD
Study NCT02622321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
Study NCT02622321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emicizumab
Description: Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.